The Kanavape ruling: what it changed for CBD in France

The case concerned a French company, Kanavape, prosecuted for marketing an electronic cigarette containing CBD produced from the whole plant, including the flowers and the leaves, at a time when French regulations only authorised the production of CBD from the seeds and the fibres of the plant. The criminal court of Marseille referred a question for a preliminary ruling to the Court of Justice of the European Union.

The Court of Justice ruled that CBD, in the current state of available scientific knowledge, had no psychotropic effect and no harmful effect on human health that would justify classifying it as a narcotic within the meaning of the international conventions. It also ruled that France could not prohibit the marketing of CBD lawfully produced in another Member State, on the basis of the principle of the free movement of goods.

Following that ruling, France had to revise its national regulations, which until then had limited CBD production to hemp fibres and seeds alone. The regulatory framework has since changed several times, notably with the decree of 30 December 2021 setting the THC threshold at 0.3 %, then the legal battle over the sale of CBD flowers, settled definitively by the Conseil d'État at the end of 2022.

The Kanavape ruling did not remain an isolated case: in its wake, several European Union Member States had to review their own national restrictions on CBD in the light of that same principle of the free movement of goods. This gradual harmonisation explains why the European CBD market has taken shape in a relatively homogeneous way since 2020, even though differences in regulation still remain from one country to another, notably on the Novel Food status of ingested products.

Several years on, the Kanavape ruling remains the basic legal reference for the CBD sector in France: it is the ruling that established that CBD is not a narcotic, opening the way to all the subsequent regulatory developments, including Novel Food status for ingested products and the more recent debates on synthetic cannabinoids.

What did the Kanavape ruling change in practice?

It established that CBD is not a narcotic and that its free movement within Europe cannot be restricted without precise health justification.

Does the Kanavape ruling authorise the sale of all CBD products?

No, it laid down a general principle. The precise rules, such as the THC threshold, Novel Food status or labelling, have continued to change since that decision.

Why did this case concern a French company?

Because Kanavape had been prosecuted in France for using the whole hemp plant, which was prohibited at the time, to produce its CBD.

Is the Kanavape ruling still applicable in 2026?

Yes, its principle remains the legal basis of the CBD sector in Europe, even though the regulations have since become more precise, notably through Novel Food status.